Streetbeat News

OBIO

Orchestra BioMed Holdings, Inc.

Industry

Biotechnology

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Open

4.25

Mkt cap

154M

Volume

37K

High

4.18

P/E Ratio

-2.53

52-wk high

8.87

Low

3.59

Div yield

N/A

52-wk low

3.76

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) will present at upcoming investor conferences, offering opportunities for one-on-one meetings with company management.

Portfolio Pulse from

February 20, 2025 | 1:15 pm

Orchestra BioMed Holdings, Inc. has appointed Dr. Vivek Reddy as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of the Bioelectronic Therapies Scientific Advisory Board. Dr. Reddy will lead the BACKBEAT global pivotal study and enhance the scientific and clinical value of the company's bioelectronic therapies.

Portfolio Pulse from

February 18, 2025 | 1:15 pm

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced that data on their AVIM therapy, which shows improvement in diastolic dysfunction, will be presented at the THT 2025 Conference. This therapy could be significant for heart failure treatment.

Portfolio Pulse from

February 12, 2025 | 4:00 pm

Orchestra BioMed Holdings, Inc. (OBIO) reported a Q3 loss of $0.41 per share, which was better than the Zacks Consensus Estimate of a $0.44 loss. This is a slight increase from the $0.38 loss per share reported a year ago.

Portfolio Pulse from

November 13, 2024 | 12:30 am

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) reported its third quarter 2024 financial results and provided a business update. The company focuses on accelerating high-impact biomedical technologies through partnerships.

Portfolio Pulse from

November 12, 2024 | 9:30 pm

HC Wainwright & Co. has initiated coverage on Orchestra BioMed Holdings with a Buy rating and set a price target of $14.